


Assessing Perinatal Mental Health



Determine Illness Severity

MODERATE

Depression screener score 15-19

Sometimes feels hopeless, helpless,

Previous psychiatric hospitalization

Some difficulty caring for self or baby

GAD-7 score 10-14

PC-PTSD-5 score ≥ 3

worthless

Suicidal ideation present

MILD

Depression screener score 10-14

GAD-7 score 5-9

PC-PTSD-5 score < 3

No suicidal ideation

Not feeling hopeless, helpless, worthless

No previous psychiatric hospitalization

No or minimal difficulty caring for self or baby

For mild, moderate, and severe illness:

- Start treatment, see page 22.

- Check for underlying medical condition - order TSH, B12, folate, Hgb, Hct

- Assess for substance use or medications which can cause or worsen mood/anxiety disorders

*If all screens are negative, tell her they were negative and say, "if something changes, please let us know. We are here."

SEVERE

Depression screener score >19

GAD-7 score >15

PC-PTSD-5 score ≥ 3

Suicidal ideation, intent and/or plan

Previous suicide attempt(s)

Often feels hopeless, helpless, worthless

History of multiple psychiatric hospitalization(s)

Often feels unable to care for self or baby

May experience hallucinations, delusions or other psychotic symptoms (e.g., major depression with psychotic features or bipolar disorder with psychotic features)

History of multiple medication trials

Continue to other side —

EPDS – Edinburgh Postnatal Depression Scale; GAD – Generalized Anxiety Disorder; MDQ – Mood Disorder Questionnaire; PHQ – Patient Health Questionnaire PTSD – Posttraumatic Stress Disorder; PC-PTSD-5 – Primary Care Post Traumatic Stress Disorder; PCL-C – PTSD Check List-Civilian

Copyright © 2019 UMass Chan Medical School all rights reserved. Revision 10-12-22. Lifeline for Moms Perinatal Mental Health Toolkit. Funding provided by CDC grant number U01DP006093. Authors: Byatt N., Mittal L., Brenckle L., Logan D., Masters G., Bergman A., Moore Simas T.



Starting Treatment for Perinatal Mental Health Conditions

Consider treatment options based on highest level of illness severity If severity of symptoms overlap, clinical decisions should be based on the assessment, with strong consideration of higher level treatment options. MILD MODERATE SEVERE Therapy referral Therapy referral Therapy referral **Consider medication treatment** Strongly consider medication treatment **Medication treatment** If onset of depression symptoms occurs in If onset of depression symptoms occurs in 3rd trimester to 4 weeks postpartum and if 3rd trimester to 4 weeks postpartum and if the patient is <6 months postpartum at the patient is <6 months postpartum at screening, consider postpartum screening, consider postpartum brexanolone (IV allopregnanolone infusion brexanolone (IV allopregnanolone infusion over 60 hours in an inpatient setting). See over 60 hours in an inpatient setting). See page 20. page 20. If you are in a mental health crisis, call the Suicide & Crisis Lifeline at 988. If you are experiencing a medical emergency, call 911. Call the Arizona Perinatal Psychiatry Access Line at 888-290-1336 Visit the APAL website at APAL.arizona.edu or APAL.ariona.edu/moms-families to find a provider in Arizona. Therapy and support options All women who screen positive, regardless of illness severity, should be referred to therapy or be advised to continue therapy Always discuss and encourage prevention and support options (e.g., peer and social supports and groups, sleep hygiene, self-care, and exercise). See page 27. How to educate patients about treatment with antidepressants Antidepressant use during pregnancy: Under-treatment or no treatment of perinatal mental health conditions: Does not appear to be linked with birth complications Has been linked with birth complications Has been linked with small but inconsistent risk of birth defects when -Can increase the risk or severity of postpartum depression taken in the first trimester, particularly paroxetine Can make it harder for moms to take care of themselves and their Has been linked with transient (days to weeks) neonatal symptoms babies (tachypnea, irritability, insomnia) Can make it harder for moms to bond with their babies Has inconsistent, overall reassuring, evidence regarding long-term Can increase risk of mental illness among offspring (months to years) neurobehavioral effects on children Has been linked with possible long-term neurobehavioral effects on children Medication treatment (when indicated) Antidepressant indicated? Yes No **Currently on antidepressant?** Refer for therapy (see above) Yes No $\sqrt{}$ ∇ \mathbf{V} **History of taking** Symptoms improving, but not 4-8 weeks of therapeutic resolved dose has not helped antidepressant that helped Yes 🗸 V No \mathbf{V} Taper and discontinue current med and Prescribe med that Start new med. On max dose for \geq 4 weeks? simultaneously start new one. See page 20. helped before See page 20. Yes ψ √ No Increase dose Maximize other treatments (e.g., therapy) In late pregnancy, consider increasing dose of antidepressant above usual therapeutic range (e.g., sertraline [Zoloft] 250 mg rather than 50-200 mg). If side effects, consider tapering and then discontinue current medication; simultaneously start new medication. See page 20. • To learn about other strategies, call Perinatal Psychiatry Access

Program or consult with or refer to psychiatric clinician.

Continue to next page



Starting Treatment for Perinatal Mental Health Conditions

Pharmacological Treatment Options for Depression, Anxiety, and PTSD

- Choose antidepressant that has worked before. If antidepressant naïve, choose antidepressant based on table below with patient
 preference in consideration. Antidepressants are similar in efficacy and side effect profile.
- In late pregnancy, you may need to increase the dose above usual therapeutic range (e.g., sertraline [Zoloft] 250mg rather than 50-200mg).
- If a patient presents with pre-existing mood and/or anxiety disorder and is doing well on an antidepressant, <u>do not</u> switch it during
 pregnancy or lactation. If patient is not doing well, see page 21.
- Evidence does not support tapering antidepressants in the third trimester.
- Minimize exposure to both illness and medication.
 - Untreated/inadequately treated illness is an exposure
 - Use lowest effective doses with goal of remission of symptoms.
 - Minimize switching of medications
 - Monotherapy preferred, when possible

See page 19 for how to educate patients about treatment with antidepressants

First-line Treatment Options for Mild, Moderate, or Severe Depression, Anxiety Disorder, and PTSD

Medication	sertraline* (Zoloft)	fluoxetine (Prozac)	citalopram** (Celexa)	escitalopram** (Lexapro)	
Starting dose and timing	25 mg	10 mg	10 mg	5 mg	
	qAM (if sedating, change to qHS)	qAM	qAM	qAM	
Initial increase after 4 days	↑ to 50 mg	↑ to 20 mg	↑ to 20 mg	↑ to 10 mg	
Second increase after 7 more days	↑ to 100 mg			_	
Reassess Monthly (increase as needed until symptoms remit)	个 by 50 mg	个 by 20 mg	↑ by 10 mg	↑ by 10 mg up to 20 mg	
Therapeutic range***	50-200 mg	20-80 mg	20-40 mg	10-20 mg	
Individualized approach to titration	Slower titration (e.g., every 10-14-days) is often needed for patients who are antidepressant naïve				

or with anxiety symptoms

*Lowest degree of passage into breast milk compared to other first-line antidepressants; **Side effects include QTc prolongation (see below); ***May need higher dose in 3rd trimester and when treating an anxiety disorder

In general, if an antidepressant has helped during pregnancy, it is best to continue it during lactation.

Prescribe a maximum of two (2) antidepressants at the same time.

Second-line Treatment Options for Mild, Moderate, or Severe Depression, Anxiety Disorder, and PTSD

Medication	duloxetine (Cymbalta)	venlafaxine (Effexor XR)	fluvoxamine (Luvox)	paroxetine (Paxil)	mirtazapine (Remeron)	bupropion HCL (Wellbutrin XL)
Starting dose and timing	30 mg*** qAM	37.5 mg qAM	25 mg qHS	10 mg*** qAM (if sedating, change to qHS)	7.5 mg qHS	150 mg qAM
Initial increase after 4 days		个 to 75 mg	个 to 50 mg	↑ to 20 mg	↑ to 15 mg	
Second increase after 7 more days	↑ to 60 mg		↑ to 100 mg			
Reassess Monthly (increase as needed until symptoms remit)	↑ by 30 mg	↑ by 75 mg	↑ by 50 mg	↑ by 10 mg	个 by 15 mg	↑ by 150 mg
Therapeutic range ***	30-120 mg	75-300 mg	50-200 mg	20-60 mg	15-45 mg	300-450 mg
Individualized approach to titration	Slower titration with anxiety syr		l-days) is often ne	eded for patients wh	o are antidepres	ssant naïve or

***May need higher dose in 3rd trimester and when treating an anxiety disorder

General side effects oral antidepressants	Temporary (days to weeks)	Long-term (weeks to months)		
	Nausea (most common)	Increased appetite/weight gain		
	Constipation/diarrhea	Sexual side effects		
	Lightheadedness	Vivid dreams/insomnia		
	Headaches	**QTc prolongation (citalopram & escitalopram)		

- Tell women to take medication with food and only increase dose if tolerating; otherwise wait until side effects dissipate before increasing. - Start medication in morning; if patient finds it sedating recommend that she takes it at bedtime

Medication Treatment for Moderate/Severe Depression with Onset in Late Pregnancy or Within 4 weeks postpartum – brexanolone (Zulresso)

Brexanolone is an FDA-approved medication that can be considered for treatment of moderate to severe postpartum depression. Brexanolone: When is Brexanolone indicated?

- is a formulation of intravenous allopregnanolone (a neurosteroid) that acts on GABA-A receptors
- requires an IV infusion over 60 hours
- has a faster onset of action (symptom reduction in 1-2 days) compared to available oral antidepressants, which generally take 4-8 weeks to work
- has been shown to maintain the reduction in depression symptoms at 30 days post-infusion

 days) compared to available oral
 Brexanolone (IV allopregnanolone infusion over 60 hours in an inpatient setting).

 on symptoms at 30 days post-infusion

More information can be found at Reprotox and LactMed on all pharmacological treatments


If onset of depression occurs in 3rd trimester

through 4 weeks postpartum and if patient is

<6 months postpartum at screening, consider



Follow-Up Treatment of Perinatal Mental Health Conditions



- Ask patient to make appointment with PCP
- Send summary to PCP
- See patient again to make sure she is in treatment with PCP

Once patient experiences remission of symptoms (e.g., 2 sequential EPDS/PHQ-9 scores <10, GAD-7 <5, PC-PTSD <3)

Can consider tapering antidepressant when patient has been in remission for \geq 6 months for depression and \geq 12 months for anxiety

Taper medication slowly to minimize risk of relapse and discontinuation syndrome

- Shorter acting medications (e.g., paroxetine [Paxil], venlafaxine [Effexor]) have higher chance of discontinuation syndrome and thus need to be tapered slowly
- o Establish postpartum birth control plan to help women make informed decision regarding family planning

Adjunctive Support Options

Talk to your patient about adjunctive support options such as:

- Self-care (See Self-Care Plan (page 27))
- Balanced nutrition and Substance avoidance
- Sleep hygiene
- Mindfulness
- Exercise
- Find resources for <u>moms and families</u> here.
- Books and workbooks (e.g., The Pregnancy and Postpartum Anxiety Workbook by Pamela S. Wiegartz and Kevin Gyoerkoe)

Social and Structural Determinants of Health

Ask about/consider social and structural factors that can be a barrier to engagement in care:

- Access to stable housing
- Access to food/safe drinking water
- Utility needs
- Safety in home and community
- Immigration status
- Employment conditions
- Transportation
- Childcare

Refer to social services as indicated